Pharsight

Drugs that contain Temozolomide

1. Temodar patents expiration

TEMODAR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5260291 MERCK SHARP DOHME Tetrazine derivatives
Aug, 2013

(10 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5260291

(Pediatric)

MERCK SHARP DOHME Tetrazine derivatives
Feb, 2014

(10 years ago)

US8623868 MERCK SHARP DOHME Processes of making and using pharmaceutical formulations of antineoplastic agents
Feb, 2023

(1 year, 2 months ago)

US7786118 MERCK SHARP DOHME Pharmaceutical formulations of antineoplastic agents
Feb, 2023

(1 year, 2 months ago)

US6987108 MERCK SHARP DOHME Pharmaceutical formulations of antineoplastic agents and processes of making and using the same
Sep, 2023

(7 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Mar 15, 2012

Market Authorisation Date: 11 August, 1999

Treatment: Treatment of malignant neoplasm

Dosage: CAPSULE;ORAL; POWDER;INTRAVENOUS

How can I launch a generic of TEMODAR before it's drug patent expiration?
More Information on Dosage

TEMODAR family patents

Family Patents